Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.41
    +0.18 (+8.07%)

    Market Cap: $506.62M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +0.20%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.11 - $0.03
    7 analysts
    EPS Revisions
    3
    0
    7d
    4
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.11+32.7%
    60d ago$-0.11+32.7%
    30d ago$-0.070.0%
    7d ago$-0.070.0%
    Current$-0.07
    Revenue Consensus
    $10M
    Range$2M - $37M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.23 - $0.01
    7 analysts
    Revenue Consensus
    $-2443120
    Range$-17216050 - $26M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.07---
    Jun 26
    Reported Aug 6
    		$-0.09$-0.11+18.18%Beat-7400.0%
    Mar 26
    Reported May 7
    		$-0.10$-0.11+9.09%Beat-137.0%
    Dec 25
    Reported Mar 16
    		$-0.22$-0.09-134.79%Miss-195.7%
    Sep 25
    Reported Nov 6
    		$-0.09$-0.04-125.00%Miss-228.6%
    Jun 25
    Reported Aug 7
    		$-0.00N/A+98.00%Beat+98.5%
    Mar 25
    Reported May 12
    		$0.27$0.13+104.24%Beat+58.8%
    Dec 24
    Reported Mar 6
    		$0.23$-0.11+309.09%Beat+2200.0%
    Sep 24
    Reported Nov 7
    		$0.07$-0.13+153.85%Beat+75.0%
    Jun 24
    Reported Aug 8
    		$-0.08$-0.06-33.33%Miss-300.0%
    Mar 24
    Reported May 8
    		$0.17$-0.06+383.33%Beat+440.0%
    Dec 23
    Reported Mar 11
    		$0.01N/A+133.33%Beat+102.3%
    Sep 23
    Reported Nov 7
    		$0.04N/A+119.05%Beat+111.4%
    Jun 23
    Reported Aug 8
    		$-0.02N/A+90.00%Beat+94.6%
    Mar 23
    Reported May 9
    		$-0.05N/A+54.55%Beat+86.5%
    Dec 22
    Reported Mar 27
    		$-0.43$-0.24-79.17%Miss-7.5%
    Sep 22
    Reported Nov 8
    		$-0.35$-0.33-6.06%Miss+0.0%
    Jun 22
    Reported Aug 4
    		$-0.37$-0.40+7.50%Beat-23.3%
    Mar 22
    Reported May 5
    		$-0.37$-0.36-2.78%Miss-42.3%
    Dec 21
    Reported Mar 1
    		$-0.40$-0.28-42.86%Miss-25.0%
    Sep 21
    Reported Nov 4
    		$-0.35$-0.30-16.67%Miss-9.4%
    Jun 21
    Reported Aug 5
    		$-0.30$-0.31+3.23%Beat+11.8%
    Mar 21
    Reported May 6
    		$-0.26$-0.35+25.71%Beat-200.0%
    Dec 20
    Reported Feb 24
    		$-0.32$-0.50+36.00%Beat+59.0%
    Sep 20
    Reported Nov 5
    		$-0.32$-0.49+34.69%Beat+38.5%
    Jun 20
    Reported Aug 6
    		$-0.34$0.03-1233.33%Miss+46.9%
    Mar 20
    Reported May 7
    		$0.26$-0.51+150.98%Beat+183.9%
    Dec 19
    Reported Feb 27
    		$-0.78$-0.47-65.96%Miss-8.3%
    Sep 19
    Reported Nov 7
    		$-0.52$-0.46-13.04%Miss+1.9%
    Jun 19
    Reported Aug 7
    		$-0.64$-0.59-8.47%Miss-82.9%
    Mar 19
    Reported May 9
    		$-0.31$-0.52+40.38%Beat+22.5%
    Dec 18
    Reported Feb 27
    		$-0.72$-0.48-50.00%Miss-2500.0%
    Sep 18
    Reported Nov 6
    		$-0.53$-0.41-29.27%Miss-89.3%
    Jun 18
    Reported Aug 8
    		$-0.35$-0.42+16.67%Beat+49.3%
    Mar 18
    Reported May 9
    		$-0.40$-0.56+28.57%Beat-73.9%
    Dec 17
    Reported Mar 7
    		$0.03N/A+106.52%Beat+107.7%
    Sep 17
    Reported Nov 7
    		$-0.28$-0.22-27.27%Miss-
    Jun 17
    Reported Aug 7
    		$-0.69$-0.33-109.09%Miss-
    Mar 17
    Reported May 5
    		$-0.23N/A+54.90%Beat-
    Dec 16
    Reported Mar 2
    		$-0.39$-0.42+7.14%Beat-

    Key Metrics

    Valuation
    P/E Ratio-4.82EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1677.00%
    ROE-37.80%ROIC-28.45%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio9.36xQuick Ratio9.36x
    Trading Statistics
    Beta2.20Avg Volume3.95M
    52-Week High$8.2152-Week Low$2.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.47
    SMA 20$2.61
    SMA 50$3.06
    SMA 200$3.98
    EMA 10$2.46
    EMA 20$2.62
    EMA 50$2.94
    EMA 200$3.43

    MACD

    Line: -0.20Signal: -0.20Hist: -0.01

    ADX

    ADX: 32.6+DI: 13.6-DI: 30.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$2.51

    Bollinger Bands

    Upper Band$2.96
    Lower Band$2.26
    %B Position2683%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    37.1

    Momentum Oscillators

    Stoch %K13.1
    Stoch %D8.3
    Williams %R-66.4
    ROC (10d)-8.4%
    Momentum-0.22
    CCI (20d)-121.4
    MFI (14d)29.0

    Volatility Measures

    ATR (14d)$0.16(6.8%)
    StdDev (20d)0.17
    Hist Vol58.1%(High)

    Volume Flow

    VWAP$2.37
    OBV178.7M
    AD Line-19.6M
    CMF (20d)-0.202

    Volume Metrics

    Avg Vol (20d)3.8M
    Vol Ratio0.8x
    VWMA (20d)$2.64

    Pivot Points

    R3$2.46
    R2$2.40
    R1$2.32
    Pivot Point$2.26
    S1$2.17
    S2$2.11
    S3$2.03

    Advanced Oscillators

    TSI-34.20
    Ultimate Osc39.7
    KST-209.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.42M$10.26M$663,000$5.96M$18.66M$50.92M$38.09M$33.43M$25.11M$41.46M$26.61M$26.38M
    Cost of Revenue$0$0$510,000$0$0$0$413,000$0$0$0$486,000$0
    Gross Profit$1.42M$10.26M$663,000$5.96M$18.66M$50.92M$38.09M$33.43M$25.11M$41.46M$26.61M$26.38M
    Operating Expenses$25.20M$29.93M$28.59M$21.73M$19.94M$28.30M$20.41M$29.32M$33.57M$29.81M$27.21M$23.26M
    R&D$17.60M$19.24M$21.23M$15.30M$13.32M$18.87M$14.79M$21.37M$25.17M$22.05M$19.39M$16.45M
    SG&A$7.60M$10.69M$7.36M$6.43M$6.62M$9.43M$5.62M$7.95M$8.39M$7.75M$7.83M$6.81M
    Operating Income$-23,781,000$-19,672,000$-27,931,000$-15,768,000$-1,286,000$22.62M$17.68M$4.11M$-8,452,000$11.66M$-606,000$3.12M
    Interest Income$3.16M$1.49M$1.48M$1.59M$1.18M$955,000$1.28M$1.69M$1.97M$2.19M$2.50M$2.70M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-20,606,000$-18,189,000$-26,455,000$-14,171,000$-91,000$23.59M$18.94M$5.80M$-6,483,000$13.84M$1.91M$5.82M
    Income Tax Expense$60,000$59,000$55,000$58,000$63,000$62,000$63,000$61,000$51,000$49,000$1.07M$2.82M
    Net Income$-20,666,000$-18,248,000$-26,510,000$-14,229,000$-154,000$23.52M$18.88M$5.74M$-6,534,000$13.79M$837,000$2.99M
    EBITDA$-25,144,000$-20,154,000$-28,145,000$-16,265,000$-1,319,000$22.56M$17.29M$3.31M$-9,433,000$10.25M$-2,337,000$1.67M
    EBIT$-23,763,000$-19,679,000$-27,936,000$-15,763,000$-1,269,000$22.63M$17.66M$4.10M$-8,454,000$11.65M$-597,000$3.12M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTMX

    News

    CytomX Therapeutics stock trades ahead of November 5 results

    CytomX Therapeutics stock is trading ahead of its anticipated third-quarter 2026 results, which MarketBeat estimates will be reported on November 5...

    ad-hoc-news.de•10/15/26•Neutral

    Cantor Fitzgerald reiterates Overweight on CytomX stock, $12 target By Investing.com

    Cantor Fitzgerald has reiterated an Overweight rating on CytomX Therapeutics (NASDAQ:CTMX) with a $12 price target...

    Investing.com Nigeria•10/13/26•Somewhat-Bullish

    Cantor Fitzgerald reiterates Overweight on CytomX stock, $12 target By Investing.com

    Cantor Fitzgerald has reiterated an Overweight rating on CytomX Therapeutics (NASDAQ: CTMX) with a $12 price target, citing the company's approach to a pivotal inflection point. Despite a 40% year-to-date stock decline...

    Investing.com Canada•10/13/26•Somewhat-Bullish

    CytomX outlines cancer strategy. CytomX Therapeutics stock trades ahead of November 5 results

    CytomX Therapeutics outlined a two-track oncology strategy based on its masked biologics platform, supported by significant cash reserves of $367 million pro forma as of July 2026...

    AD HOC NEWS•10/5/26•Neutral

    Cytomx Thera (CTMX-Q) Stock Price and News

    This article provides stock information and recent news for Cytomx Therapeutics (CTMX-Q), an oncology-focused biopharmaceutical company. It lists various news headlines from September 2026 back to May 2026...

    The Globe and Mail•10/2/26•Somewhat-Bullish

    CTMX Valuation and Fair Value

    P/E
    -4.8x
    Forward P/E
    14.2x
    PEG
    -1.8x
    P/B
    1.7x
    See GNG's fair value

    CTMX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -1677.0%
    Net margin
    0.0%
    ROIC
    -28.5%
    ROE
    -37.8%
    FCF margin
    -452.1%

    CTMX Competitors

    CompanyTicker
    Delcath Systems IncDCTH
    Tactile Systems Technology IncTCMD
    Oncology Institute IncTOI
    Evolus IncEOLS
    Evolent Health IncEVH
    Sight Sciences IncSGHT
    Puma Biotechnology IncPBYI
    Regenxbio IncRGNX

    Sector: Healthcare

    CTMX Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    3
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CTMX Bull Case vs Bear Case

    Bull case

    • CTMX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of CTMX's analyst ratings are Buy or Strong Buy.

    Bear case

    • CTMX's quarterly revenue changed -92.4% year over year.

    CTMX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    54.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 1 down

    Frequently Asked Questions About CTMX

    Does CTMX pay dividends?

    CytomX Therapeutics Inc (CTMX) does not currently pay a regular dividend.

    What is CTMX's market cap?

    CytomX Therapeutics Inc (CTMX) has a market capitalization of $506.62M with a current stock price of $2.41.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In